This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

CLINICAL AND EXPERIMENTAL RESULTS, WITH A REVIEW OF THE LITERATURE

ALEXANDER W. BLAIN, M.D.; KENNETH N. CAMPBELL, M.D.

Arch Surg. 1942;44(6):1117-1125.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Despite normal coagulation and ordinarily careful hemostasis, sufficient blood may be lost during and following operative procedures, chiefly from capillary oozing, to produce such complications as serum collection, wound infection and disruption and even postoperative shock. Delayed convalescence often results. If during or immediately after operation, a drug could safely be administered to the patient which would definitely hasten coagulation, it would constitute a valuable adjunct to mechanical hemostasis and an important advancement in operative surgery. This is true when the coagulation time is normal and more particularly so when it is delayed.

Several commercial products claimed to accelerate blood coagulation have been available for some time. Aggeler and Lucia,¹ in a recent biologic assay of seventeen of these products, found that nine were practically inactive in vitro. The only products found to be significantly active were those suitable for local or oral use. It can readily be deduced, . . . [Full Text PDF of this Article]

Author Affiliations
Professor of Clinical Surgery, Wayne University College of Medicine; DETROIT

From the Department of Surgery, Alexander Blain Hospital.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?